41 results about "Carbon monoxide-releasing molecules" patented technology

The invention discloses a photodynamic induced CO releasing method, a CO controlled delivery system and a building method thereof. The CO releasing method is characterized by carrying out controlled release of CO under irradiation of near-infrared light by mixing a photosensitizer responding to the near-infrared light and applied to photodynamic therapy with carbon monoxide releasing molecules CORM-401. The CO controlled delivery system built on the basis of the photodynamic induced CO releasing method comprises a photosensitizer responding to near-infrared light and applied to photodynamic therapy, carbon monoxide releasing molecules CORM-401 and a carrier loaded or integrated with the photosensitizer and the carbon monoxide releasing molecules CORM-401. According to the CO controlled delivery system, the photochemical effect generated by the photosensitizer under induction of the near-infrared light is capable of accelerating the CO controlled delivery system to enter cells for decomposing the nanogel under the action of glutathione in the cells and releasing CORM-401; the near-infrared light activates and simultaneously generates singlet oxygen and CO; the singlet oxygen and COare respectively applied to photodynamic therapy and CO gas therapy; the combined therapy is achieved; the anti-tumor effect is obviously improved.

Provided herein are novel carbon-monoxide releasing molecules (CO-RMs) of the Formula (I): and esters, amides, salts, solvates and hydrates thereof; wherein R1 and R2 are as described herein. Also provided are pharmaceutical compositions comprising these compounds, methods of their preparation, and their use in the treatment of liver disease and inflammation.

The present invention provides novel ruthenium compounds of Formula (I): or salts, isomers, hydrates, or solvates thereof, or combinations thereof; wherein E, R1, R2, R3, R4, R5, X1, and X2 are as defined herein, and pharmaceutical compositions thereof. Also provided are methods of use and treatment. Such compounds have been found useful in the treatment of malaria infection. Such compounds may also be useful in the treatment of inflammatory conditions, such as acute lung injury and acute respiratory distress syndrome, which optionally may be associated with a malaria infection.

The invention discloses application of carbon monoxide releasing molecules in preparing medicines for inhibiting blood coagulation activation diseases. In vivo animal experiments and in vitro cell experiments show that exogenous carbon monoxide can significantly reduce the expression of blood coagulation factors FIB and D-D in sepsis, and reduce the expression of platelet membrane glycoprotein CD 61 and CD 62p in plasma, thereby down-regulating the adhesiveness and aggregation function of platelet, inhibiting the phosphorylation level of platelet HIS of sepsis mice and finally inhibiting over activation of the coagulation system in sepsis. When the carbon monoxide releasing molecules are adopted for inhibiting over activation diseases of the coagulation system in sepsis, the concentration control is relatively easy and accurate, adding is convenient for long-term use, and the requirement of clinical application can be satisfied.

The invention provides a nanogel drug carrier for targeted delivery and consumption of a large amount of H2O2 and release of CO at the same time, and a preparation method and application thereof. Thenanogel drug carrier is a dendritic polypeptide nanogel drug carrier. The drug carrier comprises dendritic polypeptide nanogel as a carrier, and a carbon monoxide release molecules CORM401 loaded in an internal cavity of the dendritic polypeptide nanogel, and also comprises hyaluronic acid which is modified by folic acid and coats the surface of the dendritic polypeptide nanogel. A multifunctionalanti-inflammatory drug (CPHs) is prepared on the basis of the nanogel drug carrier disclosed by the invention. The drug carrier can enter activated macrophages in a HA-FA targeting manner, and rapidly release a large amount of CO is by consuming excessive H2O2. The generated CO not only can effectively inhibit cell proliferation, but also can obviously inhibit secretion of inflammatory factors byinducing activation (HO-1) of heme oxygenase and down-regulating expression of p38MAPK, NF-kB (p50 / p65) and TLR-2. The CPHs can consume a large amount of ROS at the osteoarthritis joint part, and effectively inhibit degradation of articular cartilage and extracellular matrix.

The present invention provides novel ruthenium compounds of Formula (I):or salts, isomers, hydrates, or solvates thereof, or combinations thereof; wherein E, R1, R2, R3, R4, R5, X1, and X2 are as defined herein, and pharmaceutical compositions thereof. Also provided are methods of use and treatment. Such compounds have been found useful in the treatment of malaria infection. Such compounds may also be useful in the treatment of inflammatory conditions, such as acute lung injury and acute resipiratory distress syndrome, which optionally may be associated with a malaria infection.

The invention discloses a photodynamic induced CO releasing method, a CO controlled delivery system and a building method thereof. The CO releasing method is characterized by carrying out controlled release of CO under irradiation of near-infrared light by mixing a photosensitizer responding to the near-infrared light and applied to photodynamic therapy with carbon monoxide releasing molecules CORM-401. The CO controlled delivery system built on the basis of the photodynamic induced CO releasing method comprises a photosensitizer responding to near-infrared light and applied to photodynamic therapy, carbon monoxide releasing molecules CORM-401 and a carrier loaded or integrated with the photosensitizer and the carbon monoxide releasing molecules CORM-401. According to the CO controlled delivery system, the photochemical effect generated by the photosensitizer under induction of the near-infrared light is capable of accelerating the CO controlled delivery system to enter cells for decomposing the nanogel under the action of glutathione in the cells and releasing CORM-401; the near-infrared light activates and simultaneously generates singlet oxygen and CO; the singlet oxygen and COare respectively applied to photodynamic therapy and CO gas therapy; the combined therapy is achieved; the anti-tumor effect is obviously improved.

The present invention provides a carbon monoxide donor molecule with fluorescent properties and a preparation method and application thereof. The carbon monoxide donor molecule with the structure represented by the formula (I) provided by the present invention can realize a responsive protection element in the next step under illumination conditions The removal of carbon monoxide and the release of carbon monoxide, and the carbon monoxide donor molecule can be further prepared to obtain a stable polymer, which can be further prepared into a water-stable assembly material by self-assembly. Compared with the existing carbon monoxide For releasing molecules, the carbon monoxide donor provided by the present invention has good controllable release and good biocompatibility.